Antioxidant Claim Concerns In FDA Warning To Personal Care Ingredient Firm
This article was originally published in The Tan Sheet
Executive Summary
FDA’s letter to Essential Wholesale – one of two drug claim warnings issued to cosmetics firms in November – highlights claims for non-monograph ingredients that render the firm’s offerings drugs, according to the agency. The letter followed an inspection of the company’s facility in April 2014 and a review of its website.
You may also be interested in...
Cell Vitals ‘Revolution’ Quelled? FDA Warns About Stem-Cell Claims
Claims promoting Cell Vitals’ ReLuma skin care line render the products unapproved drugs, FDA says. Marketed as “A Revolution in Stem Cell Skin Care,” the products feature cytokines and growth factors harvested from adult stem cells that send “grow and divide” signals to aging skin cells, the firms says.
National Advertising Division Shuts Down Skincarebrandsreviews Website
NourishMax agreed to discontinue “top pick” claims for its Diamond Infused Eye Cream and fold up its website that looked suspiciously to NAD like advertising in the guise of independent, honest reviews.
Cue The Class Actions! Plaintiffs React To Valisure’s Benzene Findings In Acne Drug Products
J&J, Target and Walgreens face class action complaints in California federal courts for economic harms caused by their sale of benzoyl peroxide-containing acne treatments, following Valisure’s 5 March citizen petition to the US FDA on findings of high levels of benzene in such products.